对活性蛋白C的反应不佳是先进动脉样硬化和动脉疾病的突出风险预测因子
1Department of Neurology, Innsbruck University Clinic, Innsbruck, Austria. stefan.kiechl@uibk.ac.at
Circulation
|February 9, 1999
概括
低活性蛋白C (APC) 耐药性与动脉狭窄和心血管疾病的风险增加有关. 这种关联存在于因子V莱登突变之外,突出了对血管健康的更广泛影响.
科学领域:
- 血管生物学 血管生物学
- 血栓形成研究研究
- 流行病学 流行病学
背景情况:
- 活性蛋白C (APC) 抵抗在动脉血栓形成中的作用仍然存在争议.
- 了解APC耐药性对于评估动脉疾病风险至关重要.
研究的目的:
- 调查APC耐药性与动脉样硬化血管疾病之间的关联.
- 为了确定APC抵抗是否独立地预测动脉狭窄和心血管疾病.
主要方法:
- 这是一项针对826个人的基于人口的调查.
- 高分辨率的双重超声波,用于动脉和大腿动脉.
- 评估APC反应 (APC比率) 和因子V莱登突变状态.
主要成果:
- 降低APC反应与动脉和大腿动脉狭窄的风险增加相关.
- 较低的APC比率与患心血管疾病的流行有关,无论V因子莱登突变.
- 非遗传因素在一般人群中显著影响APC反应.
结论:
- 在低APC反应和晚期动脉样硬化之间存在明显的独立关联.
- 因子V莱登突变只是APC抵抗与血管疾病联系的一个方面.
相关概念视频
Peripheral Artery Disease I: Introduction
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
